House Bill 6839
116th Congress(2019-2020)
To direct the Comptroller General of the United States to submit a report describing the response of certain entities to the COVID-19 pandemic with respect to the development, regulatory evaluation, and deployment of diagnostic tests.
Introduced
Introduced in House on May 12, 2020
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
6839
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
This bill requires the Government Accountability Office (GAO) to report on diagnostic tests to diagnose COVID-19 (i.e., coronavirus disease 2019) or detect the virus that causes the disease. Specifically, the report must describe the response of, among others, laboratories, diagnostic test manufacturers, and government entities with respect to the development, regulatory evaluation, and deployment of diagnostic tests. The GAO must also assess standards, guidance, clinical processes, and intergovernmental coordination related to COVID-19 testing.
May 12, 2020
Sort by most recent
05/12/2020
Referred to the House Committee on Energy and Commerce.
05/12/2020
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:42:56 PM